Author:
Hung Man Hsin,Wang Xin Wei
Publisher
Springer International Publishing
Reference110 articles.
1. Wong MCS, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FDH, et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep. 2017;7:45846.
https://doi.org/10.1038/srep45846
.
https://www.nature.com/articles/srep45846#supplementary-information
.
2. ClinicalTrials.gov. Interventional studies | hepatocellular carcinoma. Bethesda (MD): National Library of Medicine (US); 2018.
https://www.clinicaltrials.gov/ct2/results?cond=Hepatocellular+Carcinoma&age_v=&gndr=&type=Intr&rslt=&Search=Apply
. Accessed June 14 2018.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.
4. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
https://doi.org/10.1016/S0140-6736(16)32453-9
.
5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.
https://doi.org/10.1016/S0140-6736(18)30207-1
.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献